Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 16/20 | 0.44 |
| ▸ | PDE4A | P27815 | 13/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2985501 | 0.92 | PDE4B (0.43) | PDE4BPDE4APDE4CPDE4DPOLB | |
| SCHEMBL2987999 | 0.90 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4DPOLB | |
| SCHEMBL2986800 | 0.83 | PDE4B (0.46) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL2996793 | 0.80 | PDE4B (0.42) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL2997216 | 0.77 | CASP3 (0.42) | PDE4BPDE4APDE4CPDE4DPOLB | |
| SCHEMBL28450908 | 0.72 | PDE4B (0.52) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL29623507 | 0.72 | PDE4B (0.52) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL2097509 | 0.71 | PDE4B (0.56) | PDE4BPDE4APDE4CPDE4DFFAR4 | |
| SCHEMBL2994679 | 0.71 | LMNA (0.44) | POLB | |
| SCHEMBL17003832 | 0.71 | PDE4D (0.52) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179189-A1 | PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | ZHANG HESHENG | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179189-A1 | PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | TNF, IL1B, NOS1 | PDE4B 2498/4885PDE4A 2306/4885PDE4C 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.